CURRENT REPORT 40/2021

30 December 2021

Ryvu Therapeutics to receive from Menarini Group a development milestone based on an amended global License Agreement

The Management Board of Ryvu Therapeutics S.A. with its registered office in Kraków ("Issuer", "Company") hereby announce that today the Company and Berlin-Chemie AG with its registered office in Berlin, Germany, part of Menarini Group ("Menarini Group"), have further amended the global license agreement concluded by the parties under which Menarini Group has been granted an exclusive license to develop the SEL24 (MEN1703) ("Agreement"), about which the Issuer informed in the current report no. 4/2017 dated March 28, 2017.

The amendment clarifies certain milestone payments due under the Agreement. As a result, Issuer is due a development milestone in the amount of EUR 1.000.000,00 (PLN 4.591.500,00, converted at the exchange rate of the National Bank of Poland as of December 30, 2021 of 1 EUR = 4,5915 PLN) based on the successful achievement of an efficacy signal in IDH-mutated AML patients in the initial Dose Escalation Study and all-comers AML Expansion Cohort Study in SEL24 (MEN1703) clinical trial.

These data were reported by Menarini Group in a poster at the European Hematology Association (EHA) Congress 2021, about which the Issuer informed in current report no. 19/2021 dated June 19, 2021.

Currently SEL24(MEN1703) is being examined as part of the DIAMOND-01 trial as a single agent for the treatment of patients with Acute Myeloid Leukemia (AML). DIAMOND-01 is a First-in-Human, Phase I/II, dose escalation and cohort expansion trial of SEL24(MEN1703), investigated as a single agent for the treatment of patients with AML. In the dose escalation part of the DIAMOND-01 trial, SEL24(MEN1703) has demonstrated a manageable safety profile up to the recommended dose (RD) of 125 mg/day, along with initial evidence of antileukemic activity as single agent. This evidence has been confirmed in the cohort expansion part of the study, which also showed preliminary single agent efficacy in relapsed/refractory AML, particularly in patients with IDH mutant disease, either naïve - or previously exposed - to IDH inhibitors.

The trial is currently recruiting AML patients bearing IDH1 or IDH2 mutation, to further investigate the activity of SEL24(MEN1703) in this molecularly defined sub-population of patients.

Legal basis: Article 17 (1) of the Market Abuse Regulation (MAR)

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board